Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference

Key Points

• FT819 — Fate's off‑the‑shelf anti‑CD19 CAR‑T in Phase I/II showed no Grade ≥3 CRS/ICANS/GVHD, demonstrated B‑cell depletion and clinical signal in SLE and other autoimmune conditions, can be dosed outpatient with same‑day discharge, and has received RMAT designation with a planned potentially registration‑enabling Phase II in lupus nephritis.
• iPSC manufacturing & cash runway — Fate leverages a single iPSC master cell bank (company cites the potential for >10 million doses) and a 40,000 sq ft facility capable of producing thousands of doses (scalable to ~50,000/year), and reported >$200 million in cash with runway through 2027.
• Oncology progress — Next‑generation candidates showed early proof‑of‑concept: FT836 (nine edits targeting MICA/MICB plus CD16) was detected in blood and tumor biopsies without conditioning and produced biomarker and tumor reductions in a colorectal patient, while FT839 is IND‑enabling as a multi‑target, heavily edited program for combination approaches.

Fate Therapeutics NASDAQ: FATE used a presentation at the Needham Healthcare Conference to outline its strategy for developing “off-the-shelf” CAR T-cell therapies, highlighting clinical progress in autoimmune disease with FT819 and early proof-of-concept signals in solid tumors with FT836. President and CEO Bob Valamehr was joined by Chief Financial Officer Kamal Adawi.

Positioning CAR T as a “living drug” and the case for off-the-shelf manufacturing

Valamehr opened by describing CAR T as a “living drug” that can expand in response to antigen exposure, contrasting it with conventional drugs that may reduce disease burden but “decay over time.” He also argued that CAR T has advantages beyond expansion, including trafficking into tissues and the ability to be engineered for complex, heterogeneous diseases.

He said Fate’s approach centers on engineering induced pluripotent stem cells (iPSCs) so the company can isolate and expand a single selected clone into a master cell bank. Valamehr said this enables consistent manufacturing without repeatedly returning to donors and re-engineering starting material. He added that Fate’s current 40,000-square-foot in-house manufacturing facility can produce “thousands of doses,” and that a single iPSC master cell bank can yield “over 10 million doses.” He said the facility could produce “50,000 doses per year” with increased staffing, and supports U.S. and international clinical development.

FT819 in lupus and other autoimmune diseases: safety, early efficacy signals, and trial strategy

Valamehr focused much of the discussion on FT819, an off-the-shelf anti-CD19 CAR T-cell product candidate in a Phase I/II study in autoimmune disease. He said FT819 was designed to “balance safety and efficacy,” including placing the CAR into the TRAC locus so that CAR expression is controlled by native biology rather than a synthetic promoter.

He described two clinical approaches:

• Regimen A: a single dose of FT819 after conditioning, with multiple conditioning options. Valamehr said patients and physicians chose less intensive approaches—cyclophosphamide alone or bendamustine alone—when given the option, rather than cyclophosphamide/fludarabine (Cy/Flu).
• Regimen B: FT819 given with maintenance therapy, using less intensive conditioning or no conditioning, intended to explore potential synergy and support patients coming off maintenance therapy.

Valamehr said enrollment was initially slow due to competition and clinician familiarity with autologous CAR T processes, but accelerated after Fate shared data and sites gained experience with the company’s on-demand, outpatient approach. He emphasized that FT819 can be administered in an outpatient setting with same-day discharge.

Discussing safety, Valamehr said that as of the data cutoff there were no Grade 3 or higher cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GVHD). He also described improvements across measures including SLEDAI scores, fatigue assessments (FACIT), Physician Global Assessment (PGA), and urine protein-to-creatinine ratio (UPCR), while noting the broader CAR T field has also shown meaningful disease reductions in lupus.

He added that FT819 depleted B cells and supported an “immune reset,” with returning B-cell populations described as more naïve in nature. He also said FT819’s activity included eliminating B cells in tissues beyond blood.

Beyond systemic lupus erythematosus (SLE), Valamehr said Fate is treating patients in systemic sclerosis, vasculitis, and myositis, and shared a systemic sclerosis case study in which multiple assessments trended in the right direction.

Next steps for FT819: RMAT status and a planned lupus nephritis Phase II

Valamehr said that as of a February data cutoff the company had enrolled 15 lupus patients across seven sites, and that Fate has received Regenerative Medicine Advanced Therapy (RMAT) designation for the SLE program. He said the company has had “really good” Type B meetings with the FDA on both clinical protocol and chemistry, manufacturing, and controls (CMC) topics.

He outlined near-term priorities as completing the Phase I SLE study and continuing no-conditioning dose escalation. He also said Fate plans to pursue a Phase II single-arm, “potentially registration-enabling” study in lupus nephritis, with complete renal response at six months as the primary endpoint, first focusing on lupus nephritis and then extrarenal lupus. He said systemic sclerosis could be a subsequent Phase II opportunity if data continues to support expansion.

FT836 and FT839: next-generation engineering and combination approaches

Valamehr also described Fate’s next-generation “Sword & Shield” editing strategy, intended to avoid the need for conditioning by actively protecting allogeneic cells from host immune attack while preserving the ability to expand. He said one element uses an activating receptor targeting 4-1BB to eliminate activated immune cells that engage with the product, while another element includes knocking out CD58 to reduce adhesion and immune cell interaction.

For oncology, Valamehr highlighted FT836, which he said uses nine edits and targets stress antigens MICA and MICB. He said cancers and viruses can evade immune surveillance by cleaving MICA/MICB, and Fate designed FT836 to bind the remaining “uncleaved region.” He added FT836 includes a CD16 Fc receptor designed to enhance interaction with monoclonal antibodies, supporting combination approaches such as with cetuximab or Herceptin.

In early clinical experience at dose level one, Valamehr said Fate detected live FT836 cells in blood without conditioning and also observed evidence of trafficking to tumor tissue in a biopsy. He highlighted one colorectal cancer patient who had undergone five years of therapy without major disease reduction, where by day 29 CEA and LDH tumor biomarkers declined by more than 50%, and target lesions decreased by 20% about a month later. Valamehr said the program had moved to dose level two and that the company hoped to provide an update at ASCO.

Valamehr also discussed FT839, which he described as a “13-point edited” candidate in IND-enabling activities. He said it is designed to address more complex diseases by combining CD19 and CD38 targeting, along with CD16 to combine with monoclonal antibodies and a CD3 fusion receptor to enable combination with T-cell engagers. He said Fate hopes to treat patients in the second half of the year.

Upcoming catalysts and cash runway

In Q&A, Valamehr said Fate could support repeat dosing for FT819 if needed, describing every-six-month dosing as feasible given product availability, and adding that repeat dosing “is not a sign of weakness, it’s a sign of strength for us.” He also said the Phase II study would be based on Regimen A, stating that FT819 with bendamustine at dose level two is viewed as an “ideal combination for effective and safe treatment.”

On timelines, Valamehr said Fate expects an update at EULAR and a more comprehensive durability update at ACR, with Phase II expected to begin between those meetings. On enrollment for lupus nephritis, he said a single-arm study could be completed in 12 to 18 months and that he no longer “lose[s] sleep” over enrollment given recent acceleration.

Valamehr also said Fate has “over $200 million in cash,” which he attributed to reduced operating expenses, and stated that the company has cash runway “through 2027.”

About Fate Therapeutics NASDAQ: FATE

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.